IL161462A0 - Combinations comprising a selective cyclooxygenase-2 inhibitor - Google Patents

Combinations comprising a selective cyclooxygenase-2 inhibitor

Info

Publication number
IL161462A0
IL161462A0 IL16146202A IL16146202A IL161462A0 IL 161462 A0 IL161462 A0 IL 161462A0 IL 16146202 A IL16146202 A IL 16146202A IL 16146202 A IL16146202 A IL 16146202A IL 161462 A0 IL161462 A0 IL 161462A0
Authority
IL
Israel
Prior art keywords
inhibitor
combinations
growth factor
factor receptor
receptor tyrosine
Prior art date
Application number
IL16146202A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL161462A0 publication Critical patent/IL161462A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL16146202A 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor IL161462A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34473501P 2001-10-25 2001-10-25
US34473401P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (1)

Publication Number Publication Date
IL161462A0 true IL161462A0 (en) 2004-09-27

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16146202A IL161462A0 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Country Status (23)

Country Link
US (2) US20050043409A1 (de)
EP (1) EP1441714B1 (de)
JP (1) JP2005506366A (de)
KR (1) KR100954625B1 (de)
CN (1) CN100506224C (de)
AT (1) ATE381930T1 (de)
AU (2) AU2006252156A1 (de)
BR (1) BR0213486A (de)
CA (1) CA2464309C (de)
CY (1) CY1108045T1 (de)
DE (1) DE60224299T2 (de)
DK (1) DK1441714T3 (de)
ES (1) ES2295428T3 (de)
HK (1) HK1068261A1 (de)
HU (1) HUP0600235A3 (de)
IL (1) IL161462A0 (de)
MX (1) MXPA04003878A (de)
NZ (2) NZ532418A (de)
PL (1) PL369305A1 (de)
PT (1) PT1441714E (de)
RU (1) RU2333754C2 (de)
SI (1) SI1441714T1 (de)
WO (1) WO2003035047A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
DE602004017479D1 (de) 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
BRPI0414604A (pt) * 2003-09-23 2006-11-07 Novartis Ag combinações de um inibiddor do receptor de vegf com outros agentes terapêuticos
AU2004273615B2 (en) * 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
GEP20084572B (en) 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
BRPI0707671A2 (pt) * 2006-02-09 2011-05-10 Daiichi Sankyo Co Ltd composiÇço farmacÊutica anti-cÂncer
EP2065054A1 (de) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Kombinationen mit einem Prostaglandin und Verwendungen davon
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503395A (ja) * 1996-10-15 2001-03-13 ジー．ディー．サール アンド カンパニー 腫瘍新生の処置および予防にシクロオキシゲナーゼ―２阻害剤を使用する方法
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
AU2593600A (en) * 1998-12-23 2000-07-12 G.D. Searle & Co. Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
EP1202746B1 (de) * 1999-08-12 2006-10-04 Wyeth Holdings Corporation Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs
JP2003517475A (ja) * 1999-12-03 2003-05-27 ファイザー・プロダクツ・インク 抗炎症／鎮痛薬としてのヘテロシクロ−アルキルスルホニルピラゾール誘導体
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1259237A4 (de) * 2000-02-17 2004-07-28 Merck & Co Inc Behandlung und prophylaxe des prostatakrebs mit cox-2 selektiven inhibitoren
CA2400923A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
DE60224299T2 (de) 2008-12-11
DE60224299D1 (de) 2008-02-07
ES2295428T3 (es) 2008-04-16
PT1441714E (pt) 2008-03-10
AU2006252156A1 (en) 2007-01-18
NZ532418A (en) 2007-02-23
WO2003035047A2 (en) 2003-05-01
US20110046190A1 (en) 2011-02-24
CN1575168A (zh) 2005-02-02
SI1441714T1 (sl) 2008-06-30
HUP0600235A2 (en) 2007-02-28
US20050043409A1 (en) 2005-02-24
HUP0600235A3 (en) 2008-04-28
RU2004116069A (ru) 2005-06-10
EP1441714A2 (de) 2004-08-04
RU2333754C2 (ru) 2008-09-20
KR20040048992A (ko) 2004-06-10
BR0213486A (pt) 2005-05-10
CY1108045T1 (el) 2013-09-04
CN100506224C (zh) 2009-07-01
JP2005506366A (ja) 2005-03-03
MXPA04003878A (es) 2004-07-08
PL369305A1 (en) 2005-04-18
WO2003035047A3 (en) 2003-10-23
CA2464309C (en) 2012-01-03
KR100954625B1 (ko) 2010-04-27
EP1441714B1 (de) 2007-12-26
CA2464309A1 (en) 2003-05-01
NZ552335A (en) 2008-11-28
ATE381930T1 (de) 2008-01-15
DK1441714T3 (da) 2008-03-31
HK1068261A1 (en) 2005-04-29
AU2010200433A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
MY151032A (en) Treatment of tnf? related disorders
GB0121490D0 (en) Ciompounds
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
GB0121494D0 (en) Compounds
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2002074756A3 (de) Urokinase-inhibitoren
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
IL160382A0 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
RS37804A (en) Use of n,n-diethyl-2-/-4-(phenylmethyl)- phenoxy/ethanamine monohydrochloride (dppe)in cancer therapy
BRPI0411126A (pt) derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno
WO2001079505A3 (en) INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
AU2002348101A1 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
WO2004044226A3 (en) Induction of cellular senescence by cdk4 disruption for tumor supression and regression
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
UA67528A (en) Method for surgical treatment of thyroid cancer
EP1385497A4 (de) Verfahren zur prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n-dimethylglycin
AU2001265906A1 (en) Chemical alteration of mammal urine and mammal blood
AU2003209899A1 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases